Definium Therapeutics, Inc.
DFTX
Kedudukan dalam Saham
#3827
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Harga Saham
$32.18
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$4.32B
Perubahan (1 hari)
-6.08%
Perubahan (1 tahun)
194.25%
Negara
US
Perdagangan Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Modal pasaran bagi Definium Therapeutics, Inc.(DFTX)
Modal Pasaran: $4.32B
Sehingga October 2026, Definium Therapeutics, Inc. mempunyai modal pasaran sebanyak $4.32B. Ini menjadikan Definium Therapeutics, Inc. syarikat ke-3827th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Definium Therapeutics, Inc. dari 2020 hingga 2026
DFTX berbanding dengan 5 teratas yang paling popular stocks
